Pfizer Showcases Oncology Pipeline Advances at ESMO 2026
Event summary
- Pfizer will present data from 45 abstracts at ESMO 2026, including 11 oral presentations across breast, genitourinary, and lung cancers.
- Phase 2 results for atirmociclib in advanced breast cancer support its potential as a first-in-class treatment.
- Late-breaking overall survival data for sigvotatug vedotin in non-small cell lung cancer will be unveiled.
- Updated Phase 2 data for tivunatamig in combination with chemotherapy in first-line NSCLC will be presented.
The big picture
Pfizer's extensive data presentation at ESMO 2026 underscores its strategic focus on advancing both current standards of care and next-generation oncology treatments. The company's emphasis on breast, genitourinary, and lung cancers aligns with its goal to impact patients globally. The ongoing Phase 3 studies and planned trials highlight Pfizer's commitment to expanding its oncology portfolio through innovative therapies and strategic collaborations.
What we're watching
- Pipeline Progress
- Whether Pfizer's investigational candidates like atirmociclib and tivunatamig can secure regulatory approvals and become blockbuster therapies.
- Combination Therapies
- The pace at which Pfizer advances combination therapies, particularly with PADCEV and pembrolizumab, in various cancer indications.
- Regulatory Approvals
- The timeline for FDA's review of the sNDA for TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer.
Related topics
